Cheng-Yi Jerry Kuo
Vice General Manager UWELL BioPharma
Dr Cheng-Yi Kuo is the Vice General Manager of UWELL Biophama, Taiwan, and is involved with new product development/R&D, clinical development of cell & gene therapy and business development and corporate strategy. Dr Kuo has extensive experiences in biological product development, quality requirements and regulatory approval and clinical trial research. Dr Kuo also worked in research and development as a drug and gene delivery scientist and managed a group of scientists in that area. He has 25 years of experience in biologics development, biological product life cycle, quality and regulatory affairs. He is also an assistant professor at National Defense Medical University and Chung Yuan Christian University. He received his PhD in Pharmaceutical Biology from Monash University.
Seminars
Cell and gene therapy development is advancing toward commercialization faster than most manufacturing,
process development, analytical, and CMC teams can keep pace. This is especially evident as South Korea’s first
CAR‑T therapy enters the market.
Amid ongoing regulatory uncertainty, the primary challenge lies not in clinical performance but in supply chain and process readiness, making now a critical window to build robust, scalable, and compliant manufacturing strategies.
Join this workshop to gain key insights on:
- Systemic Agility: Mitigating material complexities and supply network volatility
- Clinical development of chimeric antigen receptor T-cell therapy manufacturing, formulation and administration
- Ensuring safety and cost efficiency in the scaled manufacturing of cell therapy products
